HomeCompareTCBPW vs HTGC

TCBPW vs HTGC: Dividend Comparison 2026

TCBPW yields 33333.33% · HTGC yields 12.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TCBPW wins by $8.428195308647591e+21M in total portfolio value
10 years
TCBPW
TCBPW
● Live price
33333.33%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.428195308647591e+21M
Annual income
$8,378,748,509,141,157,000,000,000,000.00
Full TCBPW calculator →
HTGC
Hercules Capital Inc.
● Live price
12.73%
Share price
$14.77
Annual div
$1.88
5Y div CAGR
32.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$718.3K
Annual income
$326,530.50
Full HTGC calculator →

Portfolio growth — TCBPW vs HTGC

📍 TCBPW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCBPWHTGC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCBPW + HTGC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TCBPW pays
HTGC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCBPW
Annual income on $10K today (after 15% tax)
$2,833,333.33/yr
After 10yr DRIP, annual income (after tax)
$7,121,936,232,769,983,000,000,000,000.00/yr
HTGC
Annual income on $10K today (after 15% tax)
$1,081.92/yr
After 10yr DRIP, annual income (after tax)
$277,550.93/yr
At 15% tax rate, TCBPW beats the other by $7,121,936,232,769,983,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCBPW + HTGC for your $10,000?

TCBPW: 50%HTGC: 50%
100% HTGC50/50100% TCBPW
Portfolio after 10yr
$4.2140976543237957e+21M
Annual income
$4,189,374,254,570,578,700,000,000,000.00/yr
Blended yield
99.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HTGC right now

TCBPW
No analyst data
Altman Z
-14.7
Piotroski
3/9
HTGC
Analyst Ratings
17
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$18.81
+27.4% upside vs current
Range: $17.50 — $19.75
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCBPW buys
0
HTGC buys
17
PoliticianChamberTickerTypeAmountDate
Virginia Foxx🏢 House$HTGC▼ Sell$50,001 - $100,0002026-01-12
Virginia Foxx🏢 House$HTGC▲ Buy$1,001 - $15,0002025-11-19
Virginia Foxx🏢 House$HTGC▼ Sell$15,001 - $50,0002025-09-25
Virginia Foxx🏢 House$HTGC▲ Buy$1,001 - $15,0002025-08-19
Virginia Foxx🏢 House$HTGC▲ Buy$1,001 - $15,0002025-05-20
Virginia Foxx🏢 House$HTGC▲ Buy$1,001 - $15,0002025-03-05
Virginia Foxx🏢 House$HTGC▲ Buy$1,001 - $15,0002024-11-20
Virginia Foxx🏢 House$HTGC▲ Buy$15,001 - $50,0002024-10-23
Virginia Foxx🏢 House$HTGC▲ Buy$1,001 - $15,0002024-08-20
Virginia Foxx🏢 House$HTGC▲ Buy$1,001 - $15,0002024-05-21
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCBPWHTGC
Forward yield33333.33%12.73%
Annual dividend / share$2.00$1.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.5%
Portfolio after 10y$8.428195308647591e+21M$718.3K
Annual income after 10y$8,378,748,509,141,157,000,000,000,000.00$326,530.50
Total dividends collected$8.424943808765552e+21M$623.4K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: TCBPW vs HTGC ($10,000, DRIP)

YearTCBPW PortfolioTCBPW Income/yrHTGC PortfolioHTGC Income/yrGap
1← crossover$3,344,033$3,333,333.33$12,667$1,686.53+$3.33MTCBPW
2$1,045,333,048$1,041,754,932.50$16,486$2,577.89+$1045.32MTCBPW
3$305,463,295,767$304,344,789,404.97$22,150$4,048.82+$305463.27MTCBPW
4$83,443,192,327,233$83,116,346,600,762.75$30,886$6,564.64+$83443192.30MTCBPW
5$21,308,754,850,592,396$21,219,470,634,802,260.00$44,958$11,045.93+$21308754850.55MTCBPW
6$5,087,082,937,849,453,000$5,064,282,570,159,319,000.00$68,767$19,403.05+$5087082937849.38MTCBPW
7$1,135,355,897,925,379,400,000$1,129,912,719,181,880,500,000.00$111,321$35,814.23+$1135355897925379.25MTCBPW
8$236,895,694,937,506,160,000,000$235,680,864,126,726,020,000,000.00$192,192$69,962.21+$236895694937506176.00MTCBPW
9$46,211,962,155,546,610,000,000,000$45,958,483,761,963,480,000,000,000.00$356,787$145,759.66+$46211962155546607616.00MTCBPW
10$8,428,195,308,647,591,000,000,000,000$8,378,748,509,141,157,000,000,000,000.00$718,282$326,530.50+$8.428195308647591e+21MTCBPW

TCBPW vs HTGC: Complete Analysis 2026

TCBPWStock

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Full TCBPW Calculator →

HTGCBDC

Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capital to fund acquisitions, recapitalizations and refinancing and established-stage companies. The firm provides growth capital financing solutions for capital extension; management buy-out and corporate spin-out financing solutions; company, asset specific, or intellectual property acquisition financing; convertible, subordinated and/or mezzanine loans; domestic and international corporate expansion; vendor financing; revenue acceleration by sales and marketing development, and manufacturing expansion. It provides asset-based financing with a focus on cash flow; accounts receivable facilities; equipment loans or leases; equipment acquisition; facilities build-out and/or expansion; working capital revolving lines of credit; inventory. The firm also provides bridge financing to IPO or mergers and acquisitions or technology acquisition; dividend recapitalizations and other sources of investor liquidity; cash flow financing to protect against share price volatility; competitor acquisition; pre-IPO financing for extra cash on the balance sheet; public company financing to continue asset growth and production capacity; short-term bridge financing; and strategic and intellectual property acquisition financings. It also focuses on customized financing solutions, emerging growth, mid venture, and late venture financing. The firm invests primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The firm generally seeks to invest in companies that have been operating for at least six to 12 months prior to the date of their investment. It prefers to invest in technology, energy technology, sustainable and renewable technology, and life sciences. Within technology the firm focuses on advanced specialty materials and chemicals; communication and networking, consumer and business products; consumer products and services, digital media and consumer internet; electronics and computer hardware; enterprise software and services; gaming; healthcare services; information services; business services; media, content and information; mobile; resource management; security software; semiconductors; semiconductors and hardware; and software sector. Within energy technology, it invests in agriculture; clean technology; energy and renewable technology, fuels and power technology; geothermal; smart grid and energy efficiency and monitoring technologies; solar; and wind. Within life sciences, the firm invests in biopharmaceuticals; biotechnology tools; diagnostics; drug discovery, development and delivery; medical devices and equipment; surgical devices; therapeutics; pharma services; and specialty pharmaceuticals. It also invests in educational services. The firm invests primarily in United States based companies and considers investment in the West Coast, Mid-Atlantic regions, Southeast and Midwest; particularly in the areas of software, biotech and information services. The firm prefers to invest between $10 million to $250 million in equity per transactions. It invests generally between $1 million to $40 million in companies focused primarily on business services, communications, electronics, hardware, and healthcare services. The firm invests primarily in private companies but also have investments in public companies. For equity investments, the firm seeks to represent a controlling interest in its portfolio companies which may exceed 25% of the voting securities of such companies. The firm seeks to invest a limited portion of its assets in equipment-based loans to early-stage prospective portfolio companies. These loans are generally for amounts up to $3 million but may be up to $15 million for certain energy technology venture investments. The firm allows certain debt investments have the right to convert a portion of the debt investment into equity. It also co-invests with other private equity firms. The firm seeks to exit its investments through initial public offering, a private sale of equity interest to a third party, a merger or an acquisition of the company or a purchase of the equity position by the company or one of its stockholders. The firm has structured debt with warrants which typically have maturities of between two and seven years with an average of three years; senior debt with an investment horizon of less than three years; equipment loans with an investment horizon ranging from three to four years; and equity related securities with an investment horizon ranging from three to seven years. The firm prefers to invest through its balance sheet capital. The firm formerly known as Hercules Technology Growth Capital, Inc. Hercules Capital, Inc. was founded in December 2003 and is based in Palo Alto, California with additional offices in Connecticut; Boston, Massachusetts; San Diego, California; Westport, Connecticut; Elmhurst, Illinois; Santa Monica, California; McLean, Virginia; New York, New York; Radnor, Pennsylvania; and Washington, District of Columbia and London, United Kingdom.

Full HTGC Calculator →
📬

Get this TCBPW vs HTGC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCBPW vs SCHDTCBPW vs JEPITCBPW vs OTCBPW vs KOTCBPW vs MAINTCBPW vs ARCCTCBPW vs GBDCTCBPW vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.